Royce & Associates’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Royce & Associates’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,999	Closed	-$18K	–	1193
2020 Q2	$18K	Buy	+1,999	New	+$20.7K	﹤0.01%	1122
2019 Q1	–	Sell	-623	Closed	-$9K	–	1204
2018 Q4	$9K	Buy	+623	New	+$10.2K	﹤0.01%	1141
2018 Q3	–	Sell	-431	Closed	-$6K	–	1235
2018 Q2	$6K	Buy	431 +248	+136%	+$4.36K	﹤0.01%	1211
2018 Q1	$4K	Buy	183 +105	+135%	+$2.27K	﹤0.01%	1248
2017 Q4	$2K	Buy	+78	New	+$2.5K	﹤0.01%	1244

Other funds holding OPNT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates's OPNT Position: Q3 2020 in Review

Royce & Associates sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q3 2020, closing a stake of 1,999 shares — an estimated $18K sold.

Royce & Associates first reported a position in OPNT in Q4 2017 and held it in 5 quarters. The position peaked at $18K in Q2 2020. 28 funds tracked by Wall St. Rank hold OPNT as of Q3 2020.

Royce & Associates reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Royce & Associates sold 1,999 Opiant Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $18K.
Royce & Associates first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
Royce & Associates's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $18K in Q2 2020.
28 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.